All In Biotech

Drug Trial Radar · NCT04287985

Safety and Efficacy Study of VIS649 for IgA Nephropathy

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants With Immunoglobulin A (IgA) Nephropathy

Last checked: Nov 20, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 155 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

155

Actual

Start

Jul 20, 2020

Primary completion

May 19, 2023

Study completion Jun 18, 2023

Sponsor

Sponsor type
Industry
First posted
Feb 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of VIS649 in participants with immunoglobulin A (IgA) Nephropathy (IgAN)

Conditions

  • Immunoglobulin A Nephropathy
  • Glomerular Disease
  • IgAN

Interventions

  • Dose-PlaceboDrug

    Unit Dose Strength - 0.9%.

  • Low Dose-VIS649Drug

    Dose Level = Low

  • Medium Dose-VIS649Drug

    Dose Level = Medium

  • High Dose-VIS649Drug

    Dose Level = High

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events Graded by SeverityTime frame: Baseline to End of Study (16 months)
  2. Changes From Baseline in Clinical Laboratory TestsTime frame: Baseline to End of Study (16 months)
  3. Clinically Meaningful Changes From Baseline in Vital SignsTime frame: Baseline to End of Study (16 months)
  4. Clinically Significant Physical ExaminationsTime frame: Baseline to End of Study (16 months)
  5. Change From Baseline in uPCR: Month 12Time frame: 12 months

Locations

93 sites in 15 countries. Site status is shown where the registry gives one.

  • Visterra Investigational Site

    Birmingham, Alabama

  • Visterra Investigational Site

    Los Angeles, California

  • Visterra Investigational Site

    Oxnard, California

  • Visterra Investigational Site

    Palo Alto, California

  • Visterra Investigational Site

    Stanford, California

  • Visterra Investigational Site

    Denver, Colorado

  • Visterra Investigational Site

    Lawrenceville, Georgia

  • Visterra Investigational Site

    Baton Rouge, Louisiana

  • Visterra Investigational Site

    New Orleans, Louisiana

  • Visterra Investigational Site

    Baltimore, Maryland

  • Visterra Investigational Site

    Tupelo, Mississippi

  • Visterra Investigational Site

    New York, New York

  • Visterra Investigational Site

    Chapel Hill, North Carolina

  • Visterra Investigational Site

    Columbus, Ohio

  • Visterra Investigational Site

    Bethlehem, Pennsylvania

  • Visterra Investigational Site

    Houston, Texas

  • Visterra Investigational Site

    Houston, Texas

  • Visterra Investigational Site

    New Lambton Heights, New South Wales, Australia

  • Visterra Investigational Site

    Saint Leonards, New South Wales, Australia

  • Visterra Investigational Site

    Nambour, Queensland, Australia

  • Visterra Investigational Site

    Nedlands, Western Australia, Australia

  • Visterra Investigational Site

    Calgary, Alberta, Canada

  • Visterra Investigational Site

    Brampton, Ontario, Canada

  • Visterra Investigational Site

    Montreal, Quebec, Canada

  • Visterra Investigational Site

    Hong Kong, Hong Kong

  • Visterra Investigational Site

    Kowloon, Hong Kong

  • Visterra Investigational Site

    Tsuen Wan, Hong Kong

  • Visterra Investigational Site

    Hong Kong, HK, Hong Kong

  • Visterra Investigational Site

    Chandigarh, Chandigarh, India

  • Visterra Investigational Site

    Bangalore, Karnataka, India

  • Visterra Investigational Site

    Bengaluru, Karnataka, India

  • Visterra Investigational Site

    Manipal, Karnataka, India

  • Visterra Investigational Site

    Kozhikode, Kerala, India

  • Visterra Investigational Site

    Thiruvananthapuram, Kerala, India

  • Visterra Investigational Site

    New Delhi, National Capital Territory of Delhi, India

  • Visterra Investigational Site

    Vellore, Tamil Nadu, India

  • Visterra Investigational Site

    Hyderabad, Telangana, India

  • Visterra Investigational Site

    Hyderabad, Telangana, India

  • Visterra Investigational Site

    Raebareli, Uttar Pradesh, India

  • Visterra Investigational Site

    Ashikaga-Shi, Japan

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.